Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319990 · ClinicalTrials.gov registry record
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
A clinical trial of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05319990 is a study of Type 1 Diabetes and Diabetic Kidney Disease that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05319990, a study of Type 1 Diabetes and Diabetic Kidney Disease, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic kidney disease (DKD) occurs in up to 40% of people with type 1 diabetes (T1D), often leading to kidney failure and markedly magnifying risks of cardiovascular disease and premature death. Landmark T1D kidney biopsy studies identified the classic pathological lesions of DKD, which have been attributed largely to hyperglycemia. Recent advances in continuous glucose monitoring (CGM) and automated insulin delivery have facilitated improved glycemic control, but the residual risk of DKD continues to be high. In addition, obesity and insulin resistance (IR) have accompanied intensive glycemic therapy and may promote mitochondrial dysfunction and inflammation. Deciphering the molecular underpinnings of DKD in modern-day T1D and identifying modifiable risk factors could lead to more effective and targeted therapies to prevent DKD.
Conditions Studied
Interventions
- DRUG Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
- DRUG Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319990
The ClinicalTrials.gov registry entry for NCT05319990 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF) is the first listed.
NCT05319990 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05319990 about?
NCT05319990 is a clinical study titled "Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)". Diabetic kidney disease (DKD) occurs in up to 40% of people with type 1 diabetes (T1D), often leading to kidney failure and markedly magnifying risks of cardiovascular disease and premature death. Landmark T1D kidney biopsy studies identified the classic pathological lesions of DKD, which have been ...
What is the current status of trial NCT05319990?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-03-09. Estimated completion is 2027-12-31.
What conditions does trial NCT05319990 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Complications, Autoimmune Diabetes.
What interventions are being tested in trial NCT05319990?
The interventions under investigation include: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF) (DRUG), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR) (DRUG).
Who is sponsoring clinical trial NCT05319990?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05319990 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.